Santiago Rodriguez de Cordoba

List of Publications by Year
in descending order

202 papers	24,784 citations	11651 70 h-index	7348 152 g-index
214 all docs	214 docs citations	214 times ranked	30560 citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
3	Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature, 2005, 438, 1151-1156.	27.8	1,272
4	The human complement factor H: functional roles, genetic variations and disease associations. Molecular Immunology, 2004, 41, 355-367.	2.2	514
5	C3 glomerulopathy: consensus report. Kidney International, 2013, 84, 1079-1089.	5.2	505
6	Intracellular Complement Activation Sustains T Cell Homeostasis and Mediates Effector Differentiation. Immunity, 2013, 39, 1143-1157.	14.3	444
7	Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 240-245.	7.1	429
8	Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nature Neuroscience, 2007, 10, 1407-1413.	14.8	320
9	Combined Complement Gene Mutations in Atypical Hemolytic Uremic Syndrome Influence Clinical Phenotype. Journal of the American Society of Nephrology: JASN, 2013, 24, 475-486.	6.1	308
10	Differences in reactive oxygen species production explain the phenotypes associated with common mouse mitochondrial DNA variants. Nature Genetics, 2006, 38, 1261-1268.	21.4	301
11	Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet, The, 2010, 376, 794-801.	13.7	298
12	The molecular basis of alkaptonuria. Nature Genetics, 1996, 14, 19-24.	21.4	283
13	Clustering of Missense Mutations in the C-Terminal Region of Factor H in Atypical Hemolytic Uremic Syndrome. American Journal of Human Genetics, 2001, 68, 478-484.	6.2	280
14	Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Human Molecular Genetics, 2005, 14, 703-712.	2.9	272
15	Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. Journal of Experimental Medicine, 2007, 204, 1249-1256.	8.5	267
16	Translational Mini-Review Series on Complement Factor H: Genetics and disease associations of human complement factor H. Clinical and Experimental Immunology, 2007, 151, 1-13.	2.6	252
17	Atypical aHUS: State of the art. Molecular Immunology, 2015, 67, 31-42.	2.2	236
18	New Approaches to the Treatment of Dense Deposit Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 2447-2456.	6.1	231

#	Article	IF	Citations
19	C3 glomerulopathy â€" understanding a rare complement-driven renal disease. Nature Reviews Nephrology, 2019, 15, 129-143.	9.6	223
20	Structural and Functional Characterization of Factor H Mutations Associated with Atypical Hemolytic Uremic Syndrome. American Journal of Human Genetics, 2002, 71, 1285-1295.	6.2	208
21	Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 8761-8766.	7.1	198
22	A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). Human Molecular Genetics, 1999, 8, 345-352.	2.9	196
23	Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. Journal of Clinical Investigation, 2010, 120, 3702-3712.	8.2	195
24	Characterization of complement factor Hâ€"related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood, 2009, 114, 4261-4271.	1.4	190
25	ActualizaciÃ³n en sÃndrome hemolÃtico urÃ©mico atÃpico: diagnÃ³stico y tratamiento. Documento de consenso. Nefrologia, 2015, 35, 421-447.	0.4	188
26	Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Molecular Immunology, 2004, 41, 81-84.	2.2	181
27	C3 glomerulopathyâ€"associated CFHR1 mutation alters FHR oligomerization and complement regulation. Journal of Clinical Investigation, 2013, 123, 2434-2446.	8.2	176
28	Laforin, the most common protein mutated in Lafora disease, regulates autophagy. Human Molecular Genetics, 2010, 19, 2867-2876.	2.9	170
29	Genomic Cloning and Characterization of the Human Homeobox Gene SIX6 Reveals a Cluster of SIX Genes in Chromosome 14 and Associates SIX6 Hemizygosity with Bilateral Anophthalmia and Pituitary Anomalies. Genomics, 1999, 61, 82-91.	2.9	163
30	Human genes for three complement components that regulate the activation of C3 are tightly linked.. Journal of Experimental Medicine, 1985, 161, 1189-1195.	8.5	161
31	The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Human Mutation, 2007, 28, 222-234.	2.5	160
32	Liver-Kidney Transplantation to Cure Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2009, 20, 940-949.	6.1	154
33	Genetic and environmental factors influencing the human factorï¿½H plasma levels. Immunogenetics, 2004, 56, 77-82.	2.4	145
34	A physical map of the human regulator of complement activation gene cluster linking the complement genes CR1, CR2, DAF, and C4BP.. Journal of Experimental Medicine, 1988, 167, 664-669.	8.5	144
35	De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Human Mutation, 2006, 27, 292-293.	2.5	143
36	Crystal structure of human homogentisate dioxygenase. Nature Structural Biology, 2000, 7, 542-546.	9.7	137

#	Article	IF	Citations
37	Complement analysis in the 21st century. Molecular Immunology, 2007, 44, 3838-3849.	2.2	132
38	The complotype: dictating risk for inflammation and infection. Trends in Immunology, 2012, 33, 513-521.	6.8	132
39	Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy. Human Molecular Genetics, 2012, 21, 1521-1533.	2.9	131
40	Factor H-related proteins determine complement-activating surfaces. Trends in Immunology, 2015, 36, 374-384.	6.8	130
41	Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney International, 2015, 88, 1153-1160.	5.2	130
42	Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. Journal of Immunology, 2018, 200, 2464-2478.	0.8	130
43	Regulation of glycogen synthesis by the laforinâ€“malin complex is modulated by the AMP-activated protein kinase pathway. Human Molecular Genetics, 2008, 17, 667-678.	2.9	128
44	The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Human Molecular Genetics, 2009, 18, 3452-3461.	2.9	127
45	Insights into hemolytic uremic syndrome: Segregation of three independent predisposition factors in a large, multiple affected pedigree. Molecular Immunology, 2006, 43, 1769-1775.	2.2	122
46	Genetics of Atypical Hemolytic Uremic Syndrome (aHUS). Seminars in Thrombosis and Hemostasis, 2014, 40, 422-430.	2.7	122
47	Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrology Dialysis Transplantation, 2017, 32, 466-474.	0.7	121
48	A new human Duffy blood group specificity defined by a murine monoclonal antibody. Immunogenetics and association with susceptibility to Plasmodium vivax.. Journal of Experimental Medicine, 1987, 166, 776-785.	8.5	120
49	Complement dysregulation and disease: From genes and proteins to diagnostics and drugs. Immunobiology, 2012, 217, 1034-1046.	1.9	109
50	Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. Human Molecular Genetics, 2003, 12, 3161-3171.	2.9	102
51	A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney International, 2018, 93, 450-459.	5.2	100
52	Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4366-4371.	7.1	98
53	Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney International, 2012, 82, 1084-1092.	5.2	93
54	An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia, 2013, 33, 27-45.	0.4	90

#	Article	IF	Citations
55	A Novel Atypical Hemolytic Uremic Syndromeâ€“Associated Hybrid CFHR1/CFH Gene Encoding a Fusion Protein That Antagonizes Factor Hâ€“Dependent Complement Regulation. Journal of the American Society of Nephrology: JASN, 2015, 26, 209-219.	6.1	89
56	Complement Factor H Is Expressed in Adipose Tissue in Association With Insulin Resistance. Diabetes, 2010, 59, 200-209.	0.6	88
57	Elevated factor Hâ€“related protein 1 and factor H pathogenic variants decrease complement regulation inÂIgA nephropathy. Kidney International, 2017, 92, 953-963.	5.2	87
58	Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 13504-13509.	7.1	86
59	Successful Liver-Kidney Transplantation in Two Children With aHUS Caused by a Mutation in Complement Factor H. American Journal of Transplantation, 2007, 8, 071105081616017-???.	4.7	83
60	Complement Factor H Binds to Denatured Rather than to Native Pentameric C-reactive Protein. Journal of Biological Chemistry, 2008, 283, 30451-30460.	3.4	82
61	The Complement Factor H R1210C Mutation Is Associated With Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2008, 19, 639-646.	6.1	81
62	Structural and functional analysis of mutations in alkaptonuria. Human Molecular Genetics, 2000, 9, 2341-2350.	2.9	80
63	Measurement of Factor H Variants in Plasma Using Variant-Specific Monoclonal Antibodies: Application to Assessing Risk of Age-Related Macular Degeneration. , 2008, 49, 1983.		80
64	Mutation and Polymorphism Analysis of the Human Homogentisate 1,2-Dioxygenase Gene in Alkaptonuria Patients. American Journal of Human Genetics, 1998, 62, 776-784.	6.2	79
65	The Human Homogentisate 1,2-Dioxygenase (HGO) Gene. Genomics, 1997, 43, 115-122.	2.9	78
66	The role of complement in C3 glomerulopathy. Molecular Immunology, 2015, 67, 21-30.	2.2	78
67	HLA antigens in a sample of the Spanish population: Common features among Spaniards, Basques, and Sardinians. Human Genetics, 1981, 58, 344-348.	3.8	77
68	An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document. Nefrologia, 2015, 35, 421-447.	0.4	77
69	3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 882-887.	7.1	76
70	The Molecular Basis of 3-Methylcrotonylglycinuria, a Disorder of Leucine Catabolism. American Journal of Human Genetics, 2001, 68, 334-346.	6.2	73
71	Decay-accelerating factor. Genetic polymorphism and linkage to the RCA (regulator of complement) Tj ETQq1 1 0.784314 rgBT /Over	8.5	70
72	Human T-cell lymphotropic virus type III infection in a cohort of homosexual men in New York City. JAMA - Journal of the American Medical Association, 1986, 255, 2167-2172.	7.4	70

#	Article	IF	Citations
73	Six9 (Optx2), a new member of the Six gene family of transcription factors, is expressed at early stages of vertebrate ocular and pituitary development. Mechanisms of Development, 1999, 83, 155-159.	1.7	69
74	Increased Endoplasmic Reticulum Stress and Decreased Proteasomal Function in Lafora Disease Models Lacking the Phosphatase Laforin. PLoS ONE, 2009, 4, e5907.	2.5	69
75	Antibody directs properdin-dependent activation of the complement alternative pathway in a mouse model of abdominal aortic aneurysm. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E415-22.	7.1	65
76	Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clinical and Experimental Immunology, 2000, 121, 234-241.	2.6	64
77	High Frequency of Alkaptonuria in Slovakia: Evidence for the Appearance of Multiple Mutations in HGO Involving Different Mutational Hot Spots. American Journal of Human Genetics, 2000, 67, 1333-1339.	6.2	62
78	Atypical Hemolytic Uremic Syndrome-Associated Variants and Autoantibodies Impair Binding of Factor H and Factor H-Related Protein 1 to Pentraxin 3. Journal of Immunology, 2012, 189, 1858-1867.	0.8	62
79	C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein Sâ€“independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies. Blood, 2010, 115, 4644-4650.	1.4	61
80	Complement Mutations in Diacylglycerol Kinase-Îµâ€“Associated Atypical Hemolytic Uremic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1611-1619.	4.5	61
81	A radiation hybrid map of complement factor H and factor H-related genes. Immunogenetics, 1999, 49, 549-552.	2.4	60
82	Assessment of the interaction of human complement regulatory proteins with group AStreptococcus. Identification of a high-affinity group AStreptococcus binding site in FHL-1. European Journal of Immunology, 2000, 30, 1243-1253.	2.9	59
83	Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease. EMBO Molecular Medicine, 2017, 9, 906-917.	6.9	59
84	High Frequency of Alkaptonuria in Slovakia: Evidence for the Appearance of Multiple Mutations inHGOInvolving Different Mutational Hot Spots. American Journal of Human Genetics, 2000, 67, 1333-1339.	6.2	59
85	m.6267G>A: a recurrent mutation in the human mitochondrial DNA that reduces cytochrome c oxidase activity and is associated with tumors. Human Mutation, 2006, 27, 575-582.	2.5	56
86	Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions. European Journal of Human Genetics, 2000, 8, 946-954.	2.8	55
87	The Complement Inhibitor Factor H Generates an Anti-Inflammatory and Tolerogenic State in Monocyte-Derived Dendritic Cells. Journal of Immunology, 2016, 196, 4274-4290.	0.8	54
88	Interaction between Complement Regulators andStreptococcus pyogenes: Binding of C4b-Binding Protein and Factor H/Factor H-Like Protein 1 to M18 Strains Involves Two Different Cell Surface Molecules. Journal of Immunology, 2004, 173, 6899-6904.	0.8	53
89	AMP-activated Protein Kinase Phosphorylates R5/PTG, the Glycogen Targeting Subunit of the R5/PTG-Protein Phosphatase 1 Holoenzyme, and Accelerates Its Down-regulation by the Laforin-Malin Complex. Journal of Biological Chemistry, 2009, 284, 8247-8255.	3.4	53
90	Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Molecular Immunology, 2014, 58, 77-84.	2.2	53

#	Article	IF	Citations
91	Analysis of the developmentalSIX6homeobox gene in patients with anophthalmia/microphthalmia. , 2004, 129A, 92-94.		52
92	Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome. Kidney International, 2019, 96, 995-1004.	5.2	52
93	New alleles of C4-binding protein and factor H and further linkage data in the regulator of complement activation (RCA) gene cluster in man. Immunogenetics, 1987, 25, 267-268.	2.4	51
94	Unique structure of iC3b resolved at a resolution of 24 Ã... by 3D-electron microscopy. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13236-13240.	7.1	49
95	Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome. Molecular Immunology, 2015, 67, 276-286.	2.2	49
96	Human genes for the alpha and beta chains of complement C4b-binding protein are closely linked in a head-to-tail arrangement.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 4529-4532.	7.1	48
97	The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome. Molecular Immunology, 2015, 66, 263-273.	2.2	47
98	Pleiotropic Effects of Cell Wall Amidase LytA on Streptococcus pneumoniae Sensitivity to the Host Immune Response. Infection and Immunity, 2015, 83, 591-603.	2.2	47
99	Genetic deficiency of complement factor H in a patient with age-related macular degeneration and membranoproliferative glomerulonephritis. Molecular Immunology, 2008, 45, 2897-2904.	2.2	46
100	Complete functional characterization of disease-associated genetic variants in the complement factor H gene. Kidney International, 2018, 93, 470-481.	5.2	45
101	Analysis of Alkaptonuria (AKU) Mutations and Polymorphisms Reveals that the CCC Sequence Motif Is a Mutational Hot Spot in the Homogentisate 1,2 Dioxygenase Gene (HGO). American Journal of Human Genetics, 1999, 64, 1316-1322.	6.2	43
102	Laforin and Malin Deletions in Mice Produce Similar Neurologic Impairments. Journal of Neuropathology and Experimental Neurology, 2012, 71, 413-421.	1.7	43
103	FHR-1 Binds to C-Reactive Protein and Enhances Rather than Inhibits Complement Activation. Journal of Immunology, 2017, 199, 292-303.	0.8	43
104	Variant-specific quantification of factor H in plasma identifies null alleles associated with atypical hemolytic uremic syndrome. Kidney International, 2010, 78, 782-788.	5.2	42
105	Specificity of sperm-binding Wolffian duct proteins in the rooster and their persistence on spermatozoa in the female host glands. The Journal of Experimental Zoology, 1987, 242, 189-198.	1.4	41
106	Relevance of Complement Factor Hâ€“Related 1 (CFHR1) Genotypes in Age-Related Macular Degeneration. , 2012, 53, 1087.		40
107	The Gene Coding for the Î²-Chain of C4b-Binding Protein (C4BPB) Has Become a Pseudogene in the Mouse. Genomics, 1994, 21, 501-509.	2.9	39
108	The phosphatase activity of laforin is dispensable to rescue Epm2aâ¯'/â¯' mice from Lafora disease. Brain, 2014, 137, 806-818.	7.6	38

#	Article	IF	Citations
109	Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1287-1298.	4.5	36
110	An integrated map of the human regulator of complement activation (RCA) gene cluster on 1q32. Molecular Immunology, 1999, 36, 803-808.	2.2	35
111	Genomic Cloning, Structure, Expression Pattern, and Chromosomal Location of the HumanSIX3Gene. Genomics, 1999, 55, 100-105.	2.9	35
112	Coexistence of Closed and Open Conformations of Complement Factor B in the Alternative Pathway C3bB(Mg2+) Proconvertase. Journal of Immunology, 2009, 183, 7347-7351.	0.8	35
113	Sequence and structure of the human 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase heart isoform gene (PFKFB2). FEBS Journal, 1998, 254, 103-110.	0.2	34
114	Complement factor H variants I890 and L1007 while commonly associated with atypical hemolytic uremic syndrome are polymorphisms with no functional significance. Kidney International, 2012, 81, 56-63.	5.2	34
115	Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene. Pediatric Nephrology, 2014, 29, 149-153.	1.7	34
116	Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2018, 29, 240-249.	6.1	34
117	Evidence for linkage between the loci coding for the binding protein for the fourth component of human complement (C4BP) and for the C3b/C4b receptor.. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 7890-7892.	7.1	33
118	Lessons from functional and structural analyses of disease-associated genetic variants in the complement alternative pathway. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 12-22.	3.8	33
119	The Î±7Î²0 Isoform of the Complement Regulator C4b-Binding Protein Induces a Semimature, Anti-Inflammatory State in Dendritic Cells. Journal of Immunology, 2013, 190, 2857-2872.	0.8	33
120	Hepatic disease as the first manifestation of progressive myoclonus epilepsy of Lafora. Neurology, 2007, 68, 1369-1373.	1.1	32
121	Familial Syndromic Esophageal Atresia Maps to 2p23-p24. American Journal of Human Genetics, 2000, 66, 436-444.	6.2	31
122	aHUS: a disorder with many risk factors. Blood, 2010, 115, 158-160.	1.4	31
123	Impaired autophagy in Lafora disease. Autophagy, 2010, 6, 991-993.	9.1	30
124	Coagulation factor XIII B subunit is encoded by a gene linked to the regulator of complement activation (RCA) gene cluster in man. Immunogenetics, 1988, 28, 452-454.	2.4	29
125	A high-resolution map of the regulator of the complement activation gene cluster on 1q32 that integrates new genes and markers. Immunogenetics, 1997, 45, 422-427.	2.4	29
126	Laforin, a dual-specificity phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase. Biochemical Journal, 2011, 439, 265-275.	3.7	29

#	Article	IF	Citations
127	A Humanized Antibody That Regulates the Alternative Pathway Convertase: Potential for Therapy of Renal Disease Associated with Nephritic Factors. Journal of Immunology, 2014, 192, 4844-4851.	0.8	29
128	Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management. Journal of Nephrology, 2015, 28, 641-645.	2.0	29
129	Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases. Journal of the American Society of Nephrology: JASN, 2016, 27, 1305-1311.	6.1	29
130	Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification. Blood, 2021, 138, 2185-2201.	1.4	29
131	Physical linkage of the human genes coding for complement factor H and coagulation factor XIII B subunit. Genomics, 1990, 7, 644-646.	2.9	28
132	Ochronotic rheumatism in Algeria: clinical, radiological, biological and molecular studiesâ€"a case study of 14 patients in 11 families. Joint Bone Spine, 2006, 73, 284-292.	1.6	27
133	Successful Renal Transplantation in a Patient with Atypical Hemolytic Uremic Syndrome Carrying Mutations in Both Factor I and MCP. American Journal of Transplantation, 2009, 9, 1477-1483.	4.7	26
134	Eculizumab in dense-deposit disease after renal transplantation. Pediatric Nephrology, 2014, 29, 2055-2059.	1.7	26
135	Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis. Journal of Clinical Immunology, 2016, 36, 517-527.	3.8	26
136	Human plasma C3 is essential for the development of memory B, but not T, lymphocytes. Journal of Allergy and Clinical Immunology, 2018, 141, 1151-1154.e14.	2.9	26
137	High Complement Factor H-Related (FHR)-3 Levels Are Associated With the Atypical Hemolytic-Uremic Syndrome-Risk Allele CFHR3*B. Frontiers in Immunology, 2018, 9, 848.	4.8	26
138	Complement genetics and susceptibility to inflammatory disease. Lessons from genotypeâ€"phenotype correlations. Immunobiology, 2016, 221, 709-714.	1.9	25
139	Molecular basis for factor H and FHL-1 deficiency in an Italian family. Immunogenetics, 2000, 51, 366-369.	2.4	24
140	Mutations in Proteins of the Alternative Pathway of Complement and the Pathogenesis of Atypical Hemolytic Uremic Syndrome. American Journal of Kidney Diseases, 2008, 52, 171-180.	1.9	24
141	Crystal Structure of Glyceraldehyde-3-Phosphate Dehydrogenase from the Gram-Positive Bacterial Pathogen A. vaginae, an Immunoevasive Factor that Interacts with the Human C5a Anaphylatoxin. Frontiers in Microbiology, 2017, 8, 541.	3.5	24
142	Structural insights on complement activation. FEBS Journal, 2015, 282, 3883-3891.	4.7	22
143	Malin knockout mice support a primary role of autophagy in the pathogenesis of Lafora disease. Autophagy, 2012, 8, 701-703.	9.1	21
144	Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury. American Journal of Nephrology, 2018, 48, 225-233.	3.1	21

#	Article	IF	Citations
145	Functional analysis of MCCA and MCCB mutations causing methylcrotonylglycinuria. Molecular Genetics and Metabolism, 2003, 80, 315-320.	1.1	20
146	Anti-factor H antibody affecting factor H cofactor activity in a patient with dense deposit disease. CKJ: Clinical Kidney Journal, 2012, 5, 133-136.	2.9	20
147	An ELISA assay with two monoclonal antibodies allows the estimation of free factor H and identifies patients with acquired deficiency of this complement regulator. Molecular Immunology, 2014, 58, 194-200.	2.2	20
148	Children at High Risk of Diabetes Mellitus: New York Studies of Families with Diabetes and of Children with Congenital Rubella Syndrome. Advances in Experimental Medicine and Biology, 1988, 246, 221-227.	1.6	20
149	High resolution isoelectric focusing of immunoprecipitated proteins under denaturing conditions. A simple analytical method applied to the study of complement component polymorphisms. Journal of Immunological Methods, 1984, 69, 165-172.	1.4	19
150	Molecular analyses of the HGO gene mutations in Turkish alkaptonuria patients suggest that the R58fs mutation originated from Central Asia and was spread throughout Europe and Anatolia by human migrations. Journal of Inherited Metabolic Disease, 2003, 26, 17-23.	3.6	19
151	Binding of complement regulatory proteins to Group A Streptococcus. Vaccine, 2008, 26, I75-I78.	3.8	18
152	Case report: lupus nephritis with autoantibodies to complement alternative pathway proteins and C3 gene mutation. BMC Nephrology, 2015, 16, 40.	1.8	18
153	Common and rare genetic variants of complement components in human disease. Molecular Immunology, 2018, 102, 42-57.	2.2	18
154	Familial risk of developing atypical hemolytic-uremic syndrome. Blood, 2020, 136, 1558-1561.	1.4	18
155	The crystal structure of iC3b-CR3 Î±I reveals a modular recognition of the main opsonin iC3b by the CR3 integrin receptor. Nature Communications, 2022, 13, 1955.	12.8	18
156	Genetic determinants of variation in the plasma levels of the C4b-binding protein (C4BP) in Spanish families. Immunogenetics, 2003, 54, 862-866.	2.4	17
157	Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases. Blood, 2021, 137, 3484-3494.	1.4	17
158	Definition of IDDM-associated HLA DQ and DX RFLPs by segregation analysis of multiplex sibships. Human Immunology, 1989, 24, 51-63.	2.4	16
159	Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice. Human Molecular Genetics, 2011, 20, 2571-2584.	2.9	16
160	Molecular characterization by high-resolution isoelectric focusing of the products encoded by the class II region loci of the major histocompatibility complex in humans. I. DR and DQ gene variants. Human Immunology, 1987, 20, 71-93.	2.4	15
161	Anti-C5 as Prophylactic Therapy in Atypical Hemolytic Uremic Syndrome in Living-Related Kidney Transplantation. Transplantation, 2013, 96, e26-e29.	1.0	14
162	A Novel Antibody against Human Factor B that Blocks Formation of the C3bB Proconvertase and Inhibits Complement Activation in Disease Models. Journal of Immunology, 2014, 193, 5567-5575.	0.8	14

#	Article	IF	Citations
163	Lack of association between polymorphisms in C4b-binding protein and atypical haemolytic uraemic syndrome in the Spanish population. Clinical and Experimental Immunology, 2009, 155, 59-64.	2.6	13
164	Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment. Immunobiology, 2017, 222, 363-371.	1.9	13
165	Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy. Nephrology Dialysis Transplantation, 2022, 37, 1270-1280.	0.7	13
166	Mapping of the human VLA-Î±4 gene to chromosome 2q31-q32. European Journal of Immunology, 1992, 22, 587-590.	2.9	12
167	C4BPAL1, a Member of the Human Regulator of Complement Activation (RCA) Gene Cluster That Resulted from the Duplication of the Gene Coding for the Î±-Chain of C4b-Binding Protein. Genomics, 1993, 17, 185-193.	2.9	12
168	Cloning, characterization and chromosome mapping of the human SMAP1 gene. Gene, 2002, 292, 167-171.	2.2	12
169	Membrane cofactor protein (MCP, CD46) binding to clinical isolates of Streptococcus pyogenes: Binding to M type 18 strains is independent of Emm or Enn proteins. Molecular Immunology, 2007, 44, 3571-3579.	2.2	12
170	Secondary atypical hemolytic uremic syndromes in the era of complement blockade. Kidney International, 2019, 95, 1298-1300.	5.2	12
171	Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study. CKJ: Clinical Kidney Journal, 2021, 14, 1173-1180.	2.9	12
172	Factor Hâ€“Related Protein 1 Drives Disease Susceptibility and Prognosis in C3 Glomerulopathy. Journal of the American Society of Nephrology: JASN, 2022, 33, 1137-1153.	6.1	12
173	Noncanonical immunomodulatory activity of complement regulator C4BP(Î²-) limits the development of lupus nephritis. Kidney International, 2020, 97, 551-566.	5.2	11
174	Gain-of-function mutation in complement C2 protein identified in a patient with aHUS. Journal of Allergy and Clinical Immunology, 2020, 146, 916-919.e11.	2.9	11
175	C4BPAL2: a second duplication of the C4BPA gene in the human RCA gene cluster. Immunogenetics, 1995, 41, 139-43.	2.4	10
176	The Antimicrobials Anacardic Acid and Curcumin Are Not-Competitive Inhibitors of Gram-Positive Bacterial Pathogenic Glyceraldehyde-3-Phosphate Dehydrogenase by a Mechanism Unrelated to Human C5a Anaphylatoxin Binding. Frontiers in Microbiology, 2019, 10, 326.	3.5	10
177	Expression of the ÃŸ-chain of the complement regulator C4b-binding protein in human ovary. European Journal of Cell Biology, 1999, 78, 657-664.	3.6	9
178	Expression of the peptide C4b-binding protein Â in the arthritic joint. Annals of the Rheumatic Diseases, 2006, 65, 1279-1285.	0.9	8
179	Gain-of-Function Mutations R249C and S250C in Complement C2 Protein Increase C3 Deposition in the Presence of C-Reactive Protein. Frontiers in Immunology, 2021, 12, 724361.	4.8	8
180	Does the mouse C4-binding protein gene (C4BP) map in the H-2 region?. Immunogenetics, 1985, 21, 257-265.	2.4	7

#	Article	IF	Citations
181	Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Human Molecular Genetics, 2005, 14, 1107-1107.	2.9	7
182	Blocking Complement Factor B Activation Reduces Renal Injury and Inflammation in a Rat Brain Death Model. Frontiers in Immunology, 2019, 10, 2528.	4.8	7
183	Detection of Genetic Rearrangements in the Regulators of Complement Activation RCA Cluster by High-Throughput Sequencing and MLPA. Methods in Molecular Biology, 2021, 2227, 159-178.	0.9	7
184	Complement Factor D (adipsin) Levels Are Elevated in Acquired Partial Lipodystrophy (Barraquerâ€“Simons syndrome). International Journal of Molecular Sciences, 2021, 22, 6608.	4.1	7
185	Twenty-six DRÎ², and 16 DQÎ² chain IEF variants and their associated HLA-DR, HLA-DQ, and HLA-Dw specificities. Immunogenetics, 1989, 29, 49-53.	2.4	6
186	The human CD53 gene, coding for a four transmembrane domain protein, maps to chromosomal region 1p13. Genomics, 1993, 18, 725-728.	2.9	6
187	How novel structures inform understanding of complement function. Seminars in Immunopathology, 2018, 40, 3-14.	6.1	6
188	Modulation of C4b-Binding Protein Isoforms during the Acute Phase Response Caused by Orthopedic Surgery. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1997, 27, 25-34.	0.3	5
189	Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications. European Journal of Immunology, 2017, 47, 504-515.	2.9	5
190	Ionic tethering contributes to the conformational stability and function of complement C3b. Molecular Immunology, 2017, 85, 137-147.	2.2	5
191	The Hidden Side of Complement Regulator C4BP: Dissection and Evaluation of Its Immunomodulatory Activity. Frontiers in Immunology, 2022, 13, 883743.	4.8	5
192	Absence of CD59 in Guinea Pigs: Analysis of the Cavia porcellus Genome Suggests the Evolution of a CD59 Pseudogene. Journal of Immunology, 2018, 200, 327-335.	0.8	4
193	The Relevance of the MCP Risk Polymorphism to the Outcome of aHUS Associated With C3 Mutations. A Case Report. Frontiers in Immunology, 2020, 11, 1348.	4.8	4
194	Is the atypical hemolytic uremic syndrome risk polymorphism in Membrane Cofactor Protein MCPggaac relevant in kidney transplantation? A case report. Pediatric Transplantation, 2021, 25, e13903.	1.0	4
195	Dinucleotide repeat polymorphism between the human C4BPA and C4BPB gene loci (1q32). Human Molecular Genetics, 1992, 1, 552-552.	2.9	3
196	Case Report: Combined Liver-Kidney Transplantation to Correct a Mutation in Complement Factor B in an Atypical Hemolytic Uremic Syndrome Patient. Frontiers in Immunology, 2021, 12, 751093.	4.8	3
197	Atypical hemolytic uraemic syndrome. Medicina ClÃ¬nica (English Edition), 2015, 145, 438-445.	0.2	2
198	Reply to â€œReactive oxygen species and the segregation of mtDNA sequence variantsâ€• Nature Genetics, 2007, 39, 572-572.	21.4	0

#	Article	IF	Citations
199	InvestigaciÃ³n multidisciplinar y traslacional en enfermedades raras. Arbor, 2018, 194, 468.	0.3	0
200	Preface. Molecular Immunology, 2019, 114, 312-313.	2.2	0
201	Kidney, hypertension and complement activation. In search of new therapeutic targets. Nefrologia, 2019, 39, 111-114.	0.4	0
202	RiÃ±Ã³n, hipertensiÃ³n y activaciÃ³n del complemento. En bÃºsqueda de nuevas dianas terapÃ©uticas. Nefrologia, 2019, 39, 111-114.	0.4	0